HK Stock Market Move | PEIJIA-B(09996) rose more than 10%, innovative products in large volume are expected to help accelerate the company's performance growth.

PEIJIA-B (09996) rose by more than 10%, as of press time, it rose by 9.55%, reaching HK$4.13, with a turnover of HK$1.5071 million. On the news front, at the beginning of this month, Peijia Medical announced that its subsidiary, Shanghai Jiaqi Biological Technology (Suzhou) Co., Ltd., has entered into an exclusive distribution agreement with Bioring Medical (Shanghai) International Trading Co., Ltd. Under the agreement, Jiaqi Bio has obtained the exclusive distribution rights for Bioring Medical's product SeQuent Please CIS paclitaxel-coated intracranial balloon dilation catheter (SeQuent Please CIS) in mainland China. With Jiaqi Bio's local commercialization resources and academic promotion capabilities, the group expects to accelerate the future clinical application of SeQuent Please CIS after obtaining regulatory approval and further consolidate its position in the neurovascular intervention market. China Securities Co., Ltd. pointed out that with the commercialization of the company's TaurusTrio reflux valve and the expected approval for several blockbuster innovative products such as the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair reflux product GeminiOne in 2026, the company's product portfolio in the structural heart disease field continues to enrich, and its technological leadership advantage and long-term competitiveness will be further consolidated. The neuro intervention business is expected to continue to expand revenue and profit size, contribute stable cash flow to the company, and gradually expand overseas markets. Looking ahead to 2026, the company is expected to reach a key turning point in performance growth, with accelerated revenue growth and a full-year profit turning from loss to profit.